34 Results
Hepatitis B and C—A Closer Look at NIAID Research to Accelerate Elimination
Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...
Final IAS 2023 Conversations—HIV & STI Prevention, Stigma, and U=U
As the International AIDS Society’s 12th Conference on HIV Science (IAS 2023) conference drew to a close on Wednesday, HIV.gov continued our conversations about the latest research being presented, with updates on post-exposure prophylaxis for STIs (Doxy-PEP), implementation of HIV PrEP, and the effectiveness of U=U.
IAS 2023—HIV Vaccines, bNAbs, and an Update from NIH’s Office of AIDS Research
This blog is cross-posted from HIV.gov.
On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.
NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National Institute...
Conversations at the Opening of IAS 2023
The International AIDS Society’s 12th Conference on HIV Science (IAS 2023) opened Sunday, with thousands of scientists, policy leaders, and advocates gathered to present and discuss the latest advances in HIV research. HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
IAS Conference Highlights—Heart Disease Prevention for People with HIV, Long-acting HIV Prevention and Treatment
During the first full day of sessions at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov shared conversations on important study findings about reducing cardiovascular disease among people with HIV and the latest developments with long-acting prevention and treatment options that could one day become safe and effective alternatives to daily oral pills.
Promising Advances for Antibody Treatment of Viruses that Cause Neurologic and Arthritic Diseases
NIAID scientists and colleagues are one step closer to developing a safe and effective therapy against alphaviruses, which are spread by mosquitoes and can cause two types of disease in people: causing severe neurological impairment such as encephalitis (brain swelling) or crippling muscle pain similar to arthritis.
Universal Influenza Candidate Vaccine Performs Well in Phase 1 Trial
Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.
Novel Study Model Reveals New Understanding of Fatal Familial Insomnia
Fatal familial insomnia (FFI) is a little-known yet horrific disease in which people die from lack of sleep. In a new study, NIAID scientists developed a cerebral organoid model to study the exact protein mutation that causes FFI.
NIAID-led Work Identifies Bacteria Signaling for Nerve Repair in Mice
A team of NIAID-led researchers has identified a mechanism in mice in which the immune system and commensal bacteria help repair damaged sensory neurons within the skin. They hope their findings could lead to therapies that stimulate recovery in people following skin injury and limit damage from chemotherapy and chronic diseases.
